4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020

SMi Group 11 - 12 May 2020, London, UK.
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference 2020 (HPAPI 2020) coming to London on the 11th - 12th May 2020. The conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment.

HPAPI 2020 will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.

Attend the conference and join our networking platform for industry professionals to provide you with the expertise to overcome the challenges of the HPAPI industry.

Network and learn from leading professionals such as:

Chair for 2020

  • Justin Mason-Home, Director, HPAPI Project Services Limited

Key speakers include

  • Pascal Michoux, Vice President, Global EHS Teva api & Biologics, teva API Italy
  • William Hawkins, Manager Occupation Toxicology, GsK
  • Brian Edwards, Chair, Pharmaceutical Human Factors Group, CIeHf
  • Thomas Adam, Head of GQA Chemical APIs, Bayer AG
  • Ildikó Ziegler, QA Manager, Gedeon Richter
  • Francois D’Hooge, ADC Project Manager, Gamamabs Pharma
  • Andreas Schreiner, Head of Validation, Novartis

Featured highlights

  • Explore HPAPI manufacturing with 8 big pharma from both the toxic substance and the employees’ perspective
  • Gain better understanding of human factors and ergonomics aspects and their role in improving production performance with the
  • Chartered Institute of Ergonomics and Human Factors
  • Deep dive into the oncology market and ADC production, the main driver of the HPAPI industry
  • Learn what it takes to create a safety company culture and how to better train your employees on risk perception

For further information and to register, please visit:
http://www.highlypotentapi.com/WPNEWs

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...